Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Iovance Biotherapeutics, Inc.
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Taiho Oncology, Inc.
NRG Oncology
Boston Scientific Corporation
Eastern Cooperative Oncology Group
Pfizer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
ToLymph Inc.
George Washington University
Emory University
AstraZeneca
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
AstraZeneca
Shanghai Pulmonary Hospital, Shanghai, China
University of California, San Diego
Emory University
AstraZeneca
NATCO Pharma Ltd.
Revolution Medicines, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Yonsei University
M.D. Anderson Cancer Center
NiKang Therapeutics, Inc.
Mayo Clinic
Cedars-Sinai Medical Center
University of Kentucky
Thomas Jefferson University
Genelux Corporation
Institut Bergonié
Leiden University Medical Center
Fudan University
University of California, San Diego
GlaxoSmithKline
Verrica Pharmaceuticals Inc.
Situs Cancer Research Center
Sun Yat-sen University
Regeneron Pharmaceuticals
University Health Network, Toronto
University of Utah
University of California, San Francisco
Replimune Inc.
Jinling Hospital, China